Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Liabilities and Shareholders Equity (2019 - 2025)

Benitec Biopharma has reported Liabilities and Shareholders Equity over the past 7 years, most recently at $190.7 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $190.7 million for Q4 2025, up 141.16% from a year ago — trailing twelve months through Dec 2025 was $491.5 million (up 128.55% YoY), and the annual figure for FY2025 was $99.6 million, up 90.75%.
  • Liabilities and Shareholders Equity reached $190.7 million in Q4 2025 per BNTC's latest filing, up from $96.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $190.7 million in Q4 2025 and bottomed at $4.5 million in Q2 2023.
  • Median Liabilities and Shareholders Equity over the past 5 years was $19.7 million (2022), compared with a mean of $44.0 million.
  • The largest annual shift saw Liabilities and Shareholders Equity plummeted 72.06% in 2022 before it soared 1069.58% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $14.0 million in 2021, then fell by 15.05% to $11.9 million in 2022, then soared by 79.36% to $21.4 million in 2023, then surged by 270.29% to $79.1 million in 2024, then skyrocketed by 141.16% to $190.7 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for BNTC at $190.7 million in Q4 2025, $96.0 million in Q3 2025, and $99.6 million in Q2 2025.